Analysts' recommendations : Advicenne

19/09/24

Advicenne: TP ICAP Midcap lowers its target

News in other languages : Advicenne

09-02	Advicenne poursuit sa correction boursière, la stratégie ne rassure pas
08-31	Coup dur pour Advicenne, qui retire une demande d'approbation aux USA
08-31	OHB et Soitec profitent d'une actualité porteuse, Advicenne sombre
08-31	Paris revient vers l'équilibre après un début de séance en hausse
08-31	Bourse : Airbus réfléchit à sa branche spatiale US, Soitec prépare la montée en cadence

More news

Managers and Directors : Advicenne

Manager	Title	Age	Since
Didier Laurens CEO	Chief Executive Officer	59	03/05/2021
Delphine Dumas CTO	Chief Tech/Sci/R&D Officer	-	01/09/2025
Véronique Leblanc CTO	Chief Tech/Sci/R&D Officer	-	01/04/2023

Director	Title	Age	Since
André Ulmann BRD	Director/Board Member	-	23/06/2017
Catherine Dunand BRD	Director/Board Member	64	09/03/2017
Charlotte Sibley BRD	Director/Board Member	78	20/09/2018

More insiders

Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2025, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.

Employees

Sector

Pharmaceuticals

Calendar

09-17 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
07/09/26	€0.9310	-4.02%	58,673
04/09/26	€0.9700	+0.52%	122,504
03/09/26	€0.9650	+5.46%	158,828
02/09/26	€0.9150	-11.51%	504,488
01/09/26	€1.034	-4.96%	273,061

Real-time Euronext Paris

More quotes

Analysis / Opinion

OHB and Soitec ride supportive news flow, Advicenne tumbles

August 31, 2026 at 12:54 pm

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9700EUR

Average target price

4.000EUR

Spread / Average Target

+312.37%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Euronext Paris 18:55:00 07/09/2026 +03			5-day change	1st Jan Change
0.9310 ^EUR	-4.02%		-14.43%	-46.18%

Market Cap	13.54M 15.75M 12.74M 11.63M 21.75M 1.49B 21.82M 151M 58.38M 763M 59.14M 57.85M 2.43B	P/E 2026 *	-2.06x	P/E 2027 *	-2.2x
Enterprise Value	36.64M 42.61M 34.47M 31.46M 58.84M 4.03B 59.03M 409M 158M 2.06B 160M 157M 6.57B	EV / Sales 2026 *	5.55x	EV / Sales 2027 *	5.34x
Free-Float	95.15%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	ALDVI	Real-time
Börse Stuttgart	3MM	Delayed
CBOE		Real-time
Deutsche Boerse AG	3MM	Delayed
Boerse Muenchen	3MM	Real-time
CBOE		Real-time

08-31	Advicenne Decides To Withdraw Its ADV7103 New Drug Application In The USA	CI
08-31	OHB and Soitec ride supportive news flow, Advicenne tumbles
08-31	Advicenne Withdraws US Application for Distal Renal Tubular Acidosis Drug	MT
07-21	Advicenne's Distal Renal Tubular Acidosis Medicine Secures Reimbursement in Spain	MT
07-16	Advicenne S.A. Reports Sales Results for the First Half of 2026	CI
07-02	UK Regulator Grants 'Unlimited Renewal' of Advicenne's Distal Renal Tubular Acidosis Drug	MT
07-01	Advicenne Announces Unlimited Renewal of Marketing Authorization for Sibnayal in United Kingdom	CI
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne Raises EUR4 Million from Two-tranche Bonds Issuance	MT
06-22	Advicenne S.A. Secures Its Cash Runway to Second Quarter 2027 Through A Bond Financing of A Nominal Amount of Up to EUR 3.8 Million	CI
06-01	Advicenne soars as Likozam secures social security reimbursement
06-01	Advicenne's Likozam added to France's list of reimbursable medicines

08-31	Advicenne decides to withdraw its ADV7103 New Drug Application in the USA	BU
07-20	Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain	BU
07-16	Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France	BU
07-01	Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom	BU
06-23	Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8 million	AQ

Advicenne Stock

Stocks

ALDVI

FR0013296746

Pharmaceuticals

Valuation : Advicenne

Chart: Advicenne

Latest news : Advicenne

Analysts' recommendations : Advicenne

Press Releases : Advicenne

News in other languages : Advicenne

Quotes and Performance

Price Extremes

Managers and Directors : Advicenne

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysis / Opinion

Analysts' Consensus

Annual profits - Rate of surprise

1 day	-4.02%
1 week	-14.43%
Current month	-14.43%
1 month	-43.92%
3 months	-22.03%
6 months	-50.69%
Current year	-46.18%

1 week	0.84	1.12
1 month	0.84	1.9
Current year	0.8	2.35
1 year	0.8	2.35
3 years	0.8	3.37
5 years	0.8	10.5
10 years	0.8	16.25

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/30/20 A	Nathalie Lemarié	Sell	General Counsel	998	0.0123%
12/29/20 A	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%
12/25/20 A	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADVICENNE	-4.02%	-14.43%	-26.23%	-72.29%	16.4M
REGENERON PHARMACEUTICALS, INC.	-1.87%	+4.22%	+44.36%	+1.14%	82.65B
CSL LIMITED	-0.76%	+0.50%	-17.24%	-36.14%	60.24B
MODERNA, INC.	-2.23%	+5.48%	+478.96%	+34.47%	58.11B
SAMSUNG BIOLOGICS CO.,LTD.	+1.31%	-1.35%	-7.43%	+30.97%	49.68B
UCB	-0.14%	-2.32%	-0.05%	+153.86%	46.66B
BIOGEN INC.	-1.64%	+1.07%	+56.98%	-16.26%	32.63B
INCYTE CORPORATION	-0.98%	+1.91%	+46.30%	+100.59%	25.69B
INNOVENT BIOLOGICS, INC.	-1.07%	-5.77%	-1.75%	+191.93%	22.73B
SWEDISH ORPHAN BIOVITRUM AB	-1.06%	+0.04%	+63.04%	+104.73%	16.54B
Average	-1.23%	-4.28%	+63.69%	+49.30%	39.5B
Weighted average by Cap.	-0.98%	+0.95%	+86.44%	+42.50%

	2026 *	2027 *
Net sales	6.6M 7.67M 6.21M 5.67M 10.6M 726M 10.63M 73.6M 28.45M 372M 28.82M 28.19M 1.18B	8M 9.3M 7.52M 6.87M 12.85M 880M 12.89M 89.21M 34.48M 451M 34.93M 34.17M 1.44B
Net income	-6.7M -7.79M -6.3M -5.75M -10.76M -737M -10.79M -74.72M -28.88M -377M -29.26M -28.62M -1.2B	-6.2M -7.21M -5.83M -5.32M -9.96M -682M -9.99M -69.14M -26.73M -349M -27.07M -26.48M -1.11B
Net Debt	23.1M 26.86M 21.73M 19.83M 37.09M 2.54B 37.21M 258M 99.57M 1.3B 101M 98.67M 4.14B	29.2M 33.95M 27.46M 25.07M 46.89M 3.21B 47.04M 326M 126M 1.64B 128M 125M 5.24B